Fig. 2From: Data integration to prioritize drugs using genomics and curated dataHeat map of sample stratification according to FGFR3 status in TCGA breast tumors. Breast cancer tumors are on the x-axis. Y-axis contains gene activity matrix statuses and immunohistochemical (IHC) status of ER, PR and HER2. PAM50 subtype classification is on the top-most row. FGFR inhibitors dovitinib, lenvatinib and ponatinib (dov/len/pon) share sensitive samples (green). Samples have been ordered according to FGFR inhibitor sensitivity statusBack to article page